2022 Fall Conference | C24 - Rapidly Progressive Dementia

Date Sunday 10/30/22

Time 07:30 AM - 09:00 AM PDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Michael D. Geschwind, MD, PhD, FAAN

Topic(s) Aging, Dementia, and Behavioral Neurology

Learning Objectives This course is designed to help clinicians when presented with a patient with a rapidly progressive dementia (RPD) or related syndrome to understand the evaluation pathway and how it differs from that of a typical or slowly progressive dementia syndrome; develop and apply a diagnostic algorithm for various testing, including ruling out potentially reversible or curable etiologies; and provide practical framework for diagnosis of autoimmune encephalitis.

CME Available 1.50 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge

Program Level Intermediate

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider, Neurohospitalist, Medical Student

Teaching Styles Case-based, Didactic, Audience Participation

Program Materials

Event Timeline
07:30 AM - 08:15 AM PDT	Speaker	RPD Summary and Prion Disease Michael D. Geschwind, MD, PhD, FAAN
08:15 AM - 08:45 AM PDT	Speaker	Autoimmune and Antibody-mediated Causes of RPD Jeffrey M. Gelfand, MD, MAS, FAAN
08:45 AM - 09:00 AM PDT	Q&A	Questions and Answers Michael D. Geschwind, MD, PhD, FAAN, Jeffrey M. Gelfand, MD, MAS, FAAN

Faculty Disclosures
Michael D. Geschwind, MD, PhD, FAAN	Dr. Geschwind has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Brainstorm Cell Therapeutics, Inc.. Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Walter Grubb. Dr. Geschwind has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gerson Lehrman Group. Dr. Geschwind has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Reata Pharmaceuticals, Inc..
Jeffrey M. Gelfand, MD, MAS, FAAN	Dr. Gelfand has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Arialys. Dr. Gelfand has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ventyx Bio. An immediate family member of Dr. Gelfand has received personal compensation in the range of $50,000-$99,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Headache: The Journal of Head and Face Pain. The institution of Dr. Gelfand has received research support from Genentech/Roche. The institution of Dr. Gelfand has received research support from Vigil Neurosciences. An immediate family member of Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has received publishing royalties from a publication relating to health care. Dr. Gelfand has a non-compensated relationship as a Trial Steering Committee Chairperson and member with Roche / Genentech that is relevant to AAN interests or activities.

��ɫ��

��ɫ��